IO Biotech, Inc. (IOBT), a company at the forefront of clinical-stage biopharmaceutical development, announced on Thursday the successful early completion of patient enrollment in its Phase 2 basket trial for the pioneering cancer vaccine candidate, IO102-IO103.
This Phase 2 trial evaluates the efficacy of IO102-IO103 in combination with Merck's (MRK) widely acclaimed cancer therapy, KEYTRUDA. This combination is administered both as a neoadjuvant and adjuvant treatment around the time of surgery, aiming to potentially cure individuals diagnosed with resectable melanoma or squamous cell carcinoma affecting the head and neck.
The trial has successfully recruited 93 patients across diverse regions, including the United States, Europe, and Australia. Initial outcomes from this study are expected in 2025.
Simultaneously, a global Phase 3 clinical trial examining the combined effects of IO102-IO103 and Keytruda on patients with advanced melanoma is ongoing, with preliminary results expected in the first half of 2025.
On Wednesday, IOBT's stock concluded trading at $0.85, reflecting a 3.38% decrease.
